219 results on '"Harmenberg, Ulrika"'
Search Results
2. Nuclear and stromal expression of Manic fringe in renal cell carcinoma
3. A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis
4. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature
5. Renal cell carcinoma escapes NK cell‐mediated immune surveillance through the downregulation of DNAM‐1.
6. Surgical waiting times and all-cause mortality in patients with non-metastatic renal cell carcinoma
7. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: Systematic review of the literature
8. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study
9. Surgical waiting times and all-cause mortality in patients with non-metastatic renal cell carcinoma
10. Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease : A National Register Study
11. Surgical waiting times and all-cause mortality in patients with non-metastatic renal cell carcinoma
12. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
13. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting
14. The renal cell cancer database Sweden (RCCBaSe) - a new register-based resource for renal cell carcinoma research
15. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
16. Immunogenic regions of the GA733–2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma
17. Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma
18. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma
19. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting
20. The renal cell cancer database Sweden (RCCBaSe) – a new register-based resource for renal cell carcinoma research
21. Perivascular Neuropilin‐1 expression is an independent marker of improved survival in renal cell carcinoma
22. Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis
23. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid
24. Prostate cancer cell lines lack amplification: Overexpression of HER2
25. Metastatic papillary renal cell carcinoma in the era of targeted therapy : a retrospective study from three European academic centres
26. Metastatic papillary renal cell carcinoma in the era of targeted therapy – a retrospective study from three European academic centres
27. Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012 : Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations
28. Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations
29. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
30. Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer
31. Perivascular PDGFR-β is an independent marker for prognosis in renal cell carcinoma
32. Impact of quality indicators on adherence to National and European guidelines for renal cell carcinoma
33. Metastatic papillary renal cell carcinoma : A retrospective study from two large academic centers in Sweden
34. Abstract C38: Marker-defined perivascular cells predict prognosis and response to treatment
35. Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.
36. Metastatic papillary renal cell carcinoma: A retrospective study from two large academic centers in Sweden.
37. Cancer Characteristics and Current Treatments of Patients with Renal Cell Carcinoma in Sweden
38. Overall survival (OS) in Swedish RCC patients treated 2000-2012 : Update of the RENCOMP study
39. Impact of quality indicators on adherence to National and European guidelines for renal cell carcinoma
40. Impact of quality indicators on adherence to National and European guidelines for renal cell carcinoma
41. Overall survival (OS) in Swedish RCC patients treated 2000–2012: Update of the RENCOMP study.
42. Cancer Characteristics and Current Treatments of Patients with Renal Cell Carcinoma in Sweden
43. Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
44. Perivascular PDGFR-β is an independent marker for prognosis in renal cell carcinoma.
45. Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
46. PDGFBR expression on perivascular cells influence the prognosis for TKI-treated mRCC pateints in a retrospective cohort study.
47. Curative radiation therapy in prostate cancer.
48. Treatment decision and outcome in mRCC patients with different ECOG performance status.
49. A gene expression signature to predicit overall, prostate cancer, and non–prostate cancer survival.
50. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: Single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.